CEA Antibody [SPM506] | 33-324

CEA Antibody [SPM506] | 33-324 | Gentaur UK, US & Europe Distribution

Host: Mouse

Reactivity: Human, Monkey

Homology: N/A

Immunogen: Human colon carcinoma extract was used as the immunogen for the anti-CEA antibody.

Research Area: Cancer, Cell Cycle

Tested Application: Flow, IF, IHC-P

Application: Flow Cytometry: 0.5-1 ug/million cells in 0.1ml
Immunofluorescence: 1-2 ug/ml
Immunohistochemistry (FFPE) : 0.25-0.5 ug/ml for 30 min at RT (1)
Prediluted format : incubate for 30 min at RT (2)
Optimal dilution of the anti-CEA antibody to be determined by the researcher.

1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 10-20 min followed by cooling at RT for 20 min
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required) , drip mAb solution onto the tissue section and incubate at RT for 30 min.

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: Protein G affinity chromatography

Clonality: Monoclonal

Clone: SPM506

Isotype: IgG1, kappa

Conjugate: Unconjugated

Physical State: Liquid

Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide

Concentration: 0.2 mg/mL

Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.

Alternate Name: CEACAM5 Antibody : CEA, CD66e, CEA, Carcinoembryonic antigen-related cell adhesion molecule 5, Carcinoembryonic antigen

User Note: Optimal dilutions for each application to be determined by the researcher

BACKGROUND: CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+) . Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix.